Circadian disruption increases cancer risk, but connections between circadian clocks and cancer biology are diverse and depend on tumor type. In this issue of Cancer Cell, Gonzalez-Aponte et al. demonstrate that circadian timing of glucocorticoid exposure affects glioblastoma growth. These findings underscore the importance of timing in designing therapeutic interventions.
Tarlatamab was granted conditional marketing authorization in the United Kingdom for previously treated extensive-stage small cell lung cancer.
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the…
Enrollment in the LOTIS-5 trial of loncastuximab tesirine-lpyl with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma has been completed.
Nivolumab plus ipilimumab has been approved in Europe for the frontline treatment of adult patients with MSI-H or dMMR metastatic colorectal cancer.
Despite improvements in recruitment of Latina medical students, the percentage of Latina physicians has remained stagnant, suggesting unique barriers to retention and career advancement. This…
Using a 3D co-culture system of iPSC-derived neurons and glia, termed iAssembloids, combined with CRISPRi-based screening, Li et al. investigate the effect of glial cells on…
Beyond a lengthy list of accomplishments across the leukemia spectrum of treatment, Garcia-Manero holds the importance of mentorship as incredibly dear to his heart and…
Researchers conducted a retrospective study to determine the effectiveness of internet-based postop care for patients with prostate cancer.
Colorectal cancer (CRC) remains a major global health burden, being one of the most prevalent cancers with high mortality rates. Despite advances in conventional treatment…
Experts said Durvalumab could be a ‘game changer’.
